NCT01704651View on ClinicalTrials.gov

Accelerating Gastrointestinal Recovery

PHASE3CompletedINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

October 31, 2015

Conditions
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Interventions
DRUG

Alvimopan

Perioperative administration of oral alvimopan, 12mg twice daily, starting with 1 dose preoperative.

DRUG

Placebo

Perioperative administration of placebo, at same dosing interval as study drug.

Trial Locations (1)

55905

Mayo Clinic, Rochester

All Listed Sponsors
collaborator

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

lead

Jamie N. Bakkum-Gamez

OTHER

NCT01704651 - Accelerating Gastrointestinal Recovery | Biotech Hunter | Biotech Hunter